Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 1, 2024
Language: Английский
Advanced Science, Journal Year: 2023, Volume and Issue: 10(18)
Published: April 23, 2023
Dendritic cell (DC)-based cancer immunotherapy has exhibited remarkable clinical prospects because DCs play a central role in initiating and regulating adaptive immune responses. However, the application of traditional DC-mediated is limited due to insufficient antigen delivery, inadequate presentation, high levels immunosuppression. To address these challenges, engineered biomaterials have been exploited enhance immunotherapeutic effects. In this review, vital principal components that can effects are first introduced. The parameters considered rational design biomaterials, including targeting modifications, size, shape, surface, mechanical properties, which affect biomaterial optimization DC functions, further summarized. Moreover, recent applications various field reviewed, those serve as component delivery platforms, remodel tumor microenvironment, synergistically other antitumor therapies. Overall, present review comprehensively systematically summarizes related promotion functions; specifically focuses on advances designs for activation eradicate tumors. challenges opportunities treatment strategies designed amplify via discussed with aim inspiring translation future immunotherapies.
Language: Английский
Citations
48
Cancer Reports, Journal Year: 2024, Volume and Issue: 7(3)
Published: March 1, 2024
Abstract Background Precision healthcare has entered a new era because of the developments in personalized medicine, especially diagnosis and treatment head neck squamous cell carcinoma (HNSCC). This paper explores dynamic landscape medicine as applied to HNSCC, encompassing both current future prospects. Recent Findings The integration strategies into HNSCC is driven by utilization genetic data biomarkers. Epigenetic biomarkers, which reflect modifications DNA that can influence gene expression, have emerged valuable indicators for early detection risk assessment. Treatment approaches within framework are equally promising. Immunotherapy, silencing, editing techniques, including RNA interference CRISPR/Cas9, offer innovative means modulate expression correct aberrations driving HNSCC. stem research with presents opportunities tailored regenerative approaches. synergy between technological advancements exemplified artificial intelligence (AI) machine learning (ML) applications. These tools empower clinicians analyze vast datasets, predict patient responses, optimize unprecedented accuracy. Conclusion prospects transformative approach managing this complex malignancy. By harnessing insights, immunotherapy, editing, therapies, advanced technologies like AI ML, holds key enhancing outcomes ushering precision oncology.
Language: Английский
Citations
8
MedComm, Journal Year: 2024, Volume and Issue: 5(9)
Published: Aug. 21, 2024
Head and neck cancer (HNC) is a highly aggressive type of tumor characterized by delayed diagnosis, recurrence, metastasis, relapse, drug resistance. The occurrence HNC were associated with smoking, alcohol abuse (or both), human papillomavirus infection, complex genetic epigenetic predisposition. Currently, surgery radiotherapy are the standard treatments for most patients early-stage HNC. For recurrent or metastatic (R/M) HNC, first-line treatment platinum-based chemotherapy combined antiepidermal growth factor receptor cetuximab, when resurgery radiation therapy not an option. However, curing remains challenging, especially in cases metastasis. In this review, we summarize pathogenesis including changes, abnormal signaling pathways, immune regulation mechanisms, along all potential therapeutic strategies such as molecular targeted therapy, immunotherapy, gene modifications, combination therapies. Recent preclinical clinical studies that may offer future research on also discussed. Additionally, new targets methods, antibody-drug conjugates, photodynamic radionuclide mRNA vaccines, have shown promising results trials, offering prospects
Language: Английский
Citations
6
Vaccines, Journal Year: 2023, Volume and Issue: 11(3), P. 634 - 634
Published: March 13, 2023
Therapeutic vaccination is one of the most effective immunotherapeutic approaches, second only to immune checkpoint inhibitors (ICIs), which have already been approved for clinical use. Head and neck squamous cell carcinomas (HNSCCs) are heterogenous epithelial tumors upper aerodigestive tract, a significant proportion these tend exhibit unfavorable therapeutic responses existing treatment options. Comprehending immunopathology choosing an appropriate maneuver seems be promising avenue solving this problem. The current review provides detailed overview strategies, targets, candidates in HNSCC. classical principle inducing potent, antigen-specific, cell-mediated cytotoxicity targeting specific tumor antigen mechanism vaccination, particularly against human papilloma virus positive subset However, approaches such as countering immunosuppressive microenvironment HNSCC co-stimulatory mechanisms also explored recently, with encouraging results.
Language: Английский
Citations
14
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5931 - 5931
Published: March 21, 2023
Immune modulation is a critical factor in determining the survival of patients with malignancies, including those oral squamous cell carcinoma (OSCC) and head neck SCC (HNSCC). escape or stimulation may be driven by B7/CD28 family other checkpoint molecules, forming ligand-receptor complexes immune cells tumor microenvironment. Since members can functionally compensate for counteract each other, concomitant disruption multiple OSCC HNSCC pathogenesis remains elusive. Transcriptome analysis was performed on 54 tumors 28 paired normal tissue samples. Upregulation CD80, CD86, PD-L1, PD-L2, CD276, VTCN1, CTLA4 downregulation L-ICOS relative to control were noted. Concordance expression CD28 observed across tumors. Lower ICOS indicated worse prognosis late-stage Moreover, harboring higher PD-L1/ICOS, PD-L2/ICOS, CD276/ICOS ratios had prognosis. The node-positive further worsened exhibiting between CD276 ICOS. Alterations T cell, macrophage, myeloid dendritic mast populations controls found. Decreased memory B cells, CD8+ Tregs, together increased resting NK M0 macrophages, occurred This study confirmed frequent upregulation eminent co-disruption ratio PD-L2 promising predictor patients.
Language: Английский
Citations
12
Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)
Published: Feb. 10, 2025
Oral squamous cell carcinoma (OSCC), a type of oral cancer, has high mortality rate and unfavorable outcomes. Its tumor microenvironment (TME) is intricate adaptable, with research frequently focusing on the immune reaction. Scholars are exploring ways to enhance survival by bolstering response within TME. However, comprehensive trend analysis lacking. Bibliometric can address this visualizing patterns. This study aimed map these trends in OSCC immunology from 2003 2023. An immunology-focused search was executed Web Science Core Collection, spanning Despite its narrow focus, offers telling glimpse current researches domain. performed using VOSviewer, Citespace, Scimago Graphica, R software. From 2023, field published 805 publications, predominantly China United States. The most valuable contributing author Friedman Jay, topping co-citation counts. journal Oncology leading highest publication volume. keyword bursts indicated that into nivolumab chemotherapy prevalent area interest clinical community. These findings suggest neoadjuvant immunotherapy represents promising avenue for future therapeutic development. presented summary frontiers immunological aspects OSCC. serve as reference source new insights research.
Language: Английский
Citations
0
Journal of Personalized Medicine, Journal Year: 2025, Volume and Issue: 15(4), P. 126 - 126
Published: March 25, 2025
Objective: In this overview, we present compelling evidence from multiple systematic reviews and meta-analyses (SRMAs) examine the prognostic role of PD-L1/PD-1 axis, as well potential personalized treatment strategies targeting in patients with oral squamous cell carcinoma (OSCC) potentially malignant disorders (OPMDs). Methods: Six databases were searched to retrieve review meta-analysis studies. The population interest was OSCC OPMDs whom expression PD-L1 PD-1 had been investigated. At least one following outcomes reported, along at clinicopathological feature: overall survival, disease-free or disease-specific survival. All studies assessed for risk bias using AMSTAR 2 tool. Results: A total 195 found through initial search, after duplicate removal, 97 screened by title abstract. Finally, five fit our inclusion criteria included review. Conclusions: Based on two published reviews, study revealed a lack value improving survival cancer patients. However, it showed correlation specific features such sex, lymph node metastasis, HPV status.
Language: Английский
Citations
0
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: April 23, 2025
Language: Английский
Citations
0
Cancer Immunology Immunotherapy, Journal Year: 2025, Volume and Issue: 74(6)
Published: May 3, 2025
Abstract Leukoplakia, a common type of oral dysplasia, is simply defined as white patch in the mouth or other mucosal surface. Oral dysplasia most premalignancy cavity and yet it insufficiently researched thus both diagnosing treating are still problematic issues. This study focuses on immune signature explores whether stimulating system with an therapy, vidutolimod (± checkpoint blockade (ICB)), can prevent progression even cause regression. Vidutolimod, virus-like particle encapsulating G10, believed to activate plasmacytoid dendritic cells (pDCs) through activation Toll-like receptor 9 (TLR9). To investigate this, established murine model for inducing cancer was used development response situ injection at premalignant phase. The effect treatment analyzed histologically immunologically. ELISA revealed significantly elevated levels IFN-γ, IL-12, TNF-α sera mice after 24 h one + ICB well increased proliferating T pDCs draining lymph nodes 72 third final treatment, indicating immune-boosting this therapy. Vidutolimod caused significant decrease Ki-67 expression by epithelial lesion area compared untreated mice, implicating that regime may progression.
Language: Английский
Citations
0
Journal of Cancer Research and Clinical Oncology, Journal Year: 2024, Volume and Issue: 150(3)
Published: March 25, 2024
Abstract Background Head and neck squamous cell carcinoma (HNSCC) is a significant health concern with variable global incidence linked to regional lifestyle factors HPV infections. Despite treatment advances, patient prognosis remains variable, necessitating an understanding of its molecular mechanisms the identification reliable prognostic biomarkers. Methods We analyzed 959 HNSCC samples employed batch correction obtain consistent transcriptomic data across cohorts. examined 79 disulfidptosis-related genes determine consensus clusters utilized high-throughput sequencing identify genetic heterogeneity within tumors. established disulfidptosis signature (DSPS) using least absolute shrinkage selection operator (LASSO) regression developed nomogram integrating DSPS clinical factors. Personalized chemotherapy prediction was performed "pRRophetic" R package. Results Batch corrections were used harmonize gene expression data, revealing two distinct subtypes, C1 C2, differential survival outcomes. Subtype C1, characterized by increased MYH family ACTB, ACTN2, FLNC, had mortality rate 48.4%, while subtype C2 38.7% (HR = 0.77, 95% CI: 0.633–0.934, P 0.008). LASSO identified 15 that composed model, which independently predicted 2.055, 1.420–2.975, < 0.001). The nomogram, included DSPS, age, tumor stage, AUC values 0.686, 0.704, 0.789 at 3, 5, 8 years, respectively, indicating strong predictive capability. In external validation cohort (cohort B), successfully patients greater risk, worse overall outcomes in high-DSPS subgroup 1.54, 1.17–2.023, 0.002) 0.601, 0.644, 0.636, 0.748 8, 10 confirming model's robustness. Conclusion provides robust tool for HNSCC, underscoring complexity this disease potential tailored strategies. This study highlights importance signatures oncology, offering step toward personalized medicine improved management.
Language: Английский
Citations
3